Industry News


RAJ K. CHOPRA honored by The American College of Nutrition

Westbury, NY (October 10, 2006)

photo-announcements-acn.gifThe American College of Nutrition (ACN) honored Raj K. Chopra as the 2006 Industry Recipient of the prestigious Bieber Award "in recognition of his outstanding academic accomplishments and distinguished contributions in the nutrition industry". The 47th Annual ACN President's Dinner and Awards Presentation was held on Saturday, October 7th, 2006 at the Grand Sierra Resort in Reno, Nevada. His wife, Asha Chopra, accompanied him.

Raj K. Chopra is a leading authority on health foods and vitamin supplements in the USA. He is acknowledged to be one of the world's experts in chewable multivitamin formulations, timed-release formulations and bioenhanced supplements. He has been instrumental in providing support for ACN through Tishcon as a National Nutrition Alliance member for years. Chopra continues to serve as Chairman/CEO and Chief Scientific Officer of Tishcon Corporation.

Prior to establishing Tishcon, Raj K. Chopra received the Gold Medal for Outstanding Academic Merit and University First Rank recognition from L. M. College of Pharmacy in India. Mr. Chopra taught Industrial Pharmacy at Columbia University, where he received a full scholarship for his graduate studies, and later served as Technical Director of Private Formulations, Inc.

Tishcon Corp., founded in 1976, is a leading manufacturer and marketer of vitamins, related dietary and herbal supplements and private label non-prescription (OTC) pharmaceuticals in tablet, hard gelatin capsule, soft gelatin capsule and powder dosage forms. Tishcon, a contract manufacturer and private label supplier, is a leading soft gelatin capsule manufacturer in the USA. A full service manufacturer, Tishcon also specializes in enhancing bioavailability of supplements. Revolutionary technological developments include Bio Solv – hydrosoluble softgels, which enable quick and optimum absorption of vitamins and related co-factors.

In conjunction with Vitamin Relief USA, Tishcon provides free multivitamins each day for more than 14,000 children at risk for malnutrition and over 2500 at-risk homeless adults and senior citizens. According to parents and teachers, Tishcon's vitamins have dramatically improved the quality of life and health of the children served by this program. In addition to the children's program, Tishcon makes an annual donation of two million adult vitamins to Vitamin Relief USA's Senior Support program. Further, Tishcon donates the warehousing and shipping of these vitamins to the hundreds of distribution sites. In 2005, Honorable Congressman Frank Pallone, Jr. of NJ recognized the outstanding humanitarian accomplishments of Tishcon "an exemplary model of corporate humanity and citizenship" in the House of Representatives.

Tishcon Corp. is registered with the U.S. FDA, NY State Board of Pharmacy, and is GMP Certified by NPA and by NSF. Tishcon's Q-Gel® and related Coenzyme Q10 products have also passed consumerlab.com's rigorous testing.

The Bieber Awards honor the memory of a special member of the American College of Nutrition, Dr. Mark Bieber. Dr. Bieber received his PhD in Biochemistry from Michigan State in 1973. After four years as a Postdoctoral Fellow at NIH, he joined Bestfoods (now Unilever Bestfoods), where his responsibilities within the Nutrition Department included reviewing all medical and consumer publicity matters as well as advertising and nutrition labeling information. He was also incredibly active in a host of professional organizations, including AHA, IFT and AOCS, as well as the ACN.

The American College of Nutrition (A.C.N.) was established in 1959 to promote scientific investigation in the field of nutritional sciences. A.C.N. publishes, bi-monthly, the Journal of the American College of Nutrition. http://www.amcollnutr.org


FDA Sponsored Phase 3 Trial of LIQ-NOL® in Mitochondrial Diseases

This study is sponsored by the FDA Orphan Products Division, Tishcon Corp., & General Clinical Research Centers funded by the National Institutes of Health.

Study Information
The study will help provide information to determine if Coenzyme Q10 (CoQ10) is a safe and effective treatment for children with mitochondrial diseases. There are no cures for mitochondrial diseases at this time. Treatments have sought to help reduce the symptoms or delay the progression of the disease. CoQ10 is a mitochondrial cofactor and antioxidant that is a part of the process by which food and oxygen are converted into energy by cells.

Eligibility
Children age 12 months to 17 years with biochemical or genetic proof of a mitochondrial disease. There are factors that could exclude some children with a mitochondrial disorder from participating. Ask the study coordinator if your child is eligible to participate.

If your child is not eligible, that dose not mean that he/she does not have a mitochondrial disorder, as there are many specific factors that are part of the selection process.

Participation
Your participation is important because: It will contribute to medical knowledge about mitochondrial diseases, help determine the benefit of CoQ10 in treating mitochondrial diseases, and help future clinical research trials look for specific treatments for people with mitochondrial deficiencies.

Potential Benefits
  • 1) Developmental evaluation of your child
  • 2) Evaluation of his/her motor skills
  • 3) Objective evaluation of effectiveness of CoQ10
Participating Centers
  • General Clinical Research Center, University of Florida, Gainesville, Florida
  • William T. Dahms Clinical Research Unit, University Hospitals Case Medical Center, Cleveland, Ohio
  • Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
  • Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

Results of ConsumerLab.com Coenzyme Q10 tests published:

Tishcon's Hydro Q Sorb 20% CoQ10 powder obtains certification from Consumer Labs (CL).
View Results


Tishcon obtains Orphan Drug Designation for Ubiquinol from the US FDA:

WESTBURY, N.Y., April 19 / PRNewswire / -- Tishcon Corp. announced that the U.S. FDA has granted the firm Orphan Drug Designations for UBIQUINOL (Coenzyme Q10) in the treatment of Pediatric Congestive Heart Failure and Huntington's Disease.


Q-Gel Patent Granted:

q-gel-logo.gif Biosytes, Inc. was awarded United States Patent 6,056,971 for the Bio-Solv process used to enhance the bioavailability and absorption of Coenzyme Q10.
Tishcon Corporation, Westbury, NY has the exclusive worldwide rights to the patented process. The Bio-Solv process is used in Tishcon's Q-Gel Coenzyme Q10 formulas. It improves absorption by making CoQ10 virtually water soluble (hydrosoluble) and by reducing its particle size. Human clinical studies have shown that the Bio-Solv process used in the Q-Gel formulation makes CoQ10 several times more bioavailable than conventional supplement forms.

VITA VIDEOS

icon-video.png

Vitamin Angels founder and president, Howard Schiffer, thanks Tishcon Corp. for their support.

WATCH

VITA SEARCH

icon-search.png

VitaSearch® is your best source for searching information on natural health and wellness.

SEARCH

VITA LINKS

icon-link.png

VitaLinks offers a host of online resources and links geared towards all aspects of life. Click to find out more!

Learn